


AHPBA Sponsored Consensus Conference on the



Multidisciplinary Treatment of Bile Duct Cancer

Wednesday, January 15, 2014

San Francisco Marriott Marquis
55 Fourth Street
San Francisco, California



Multidisciplinary Treatment of Bile Duct Cancer (BDC)

Wednesday, January 15, 2014 San Francisco Marriott Marquis


55 Fourth Street • San Francisco, California

Goal

The focus of this consensus conference is the multidisciplinary management of patients with bile duct cancers. The aim of this conference is to review the current indications for surgical treatment, non-surgical interventions, and adjuvant therapy for bile duct cancer. This topic has not previously been discussed in a consensus conference format, and therefore, there is likely to be a high education yield for participants. The format will divide the conference into three sessions, individually focusing on Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer. The program features an expert multispecialty international group of speakers, panelists,

and moderators with extensive experience in the diagnosis, staging, treatment, and research related to the state-of-the-art treatment of patients with bile duct malignancy. The goal of this meeting is to provide a forum to review, discuss, and establish current practice guidelines and consensus statements. At the conclusion of the conference, attendees should leave with a higher level of understanding and competence in the diagnosis and management of these disorders.

* Not an official event of the 2014 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the 2014 Gastrointestinal Cancers Symposium.



Educational Objectives

After attending the conference, participants should be able to

- Appropriately apply diagnostic and staging modalities to bile duct cancer patients (*Knowledge, Competence, Performance*);
- Appropriately select the proper surgical treatment modalities available for the management of bile duct cancer (*Knowledge, Competence, Performance*);
- Appropriately select and sequence the best multiple interventional and nonsurgical treatment modalities available for optimal management of bile duct cancer (*Knowledge, Competence, Performance, Patient Outcomes*);
- Appropriately implement the most up-to-date systemic cytotoxic and biologic strategies in the management of bile duct cancer to improve patient outcomes (*Knowledge, Competence, Performance, Patient Outcomes*).

Target Audience


This conference will be beneficial to surgical oncologists, medical oncologists, radiologists, and interventional radiologists.

Educational Methods

Lectures – Question and Answer – Panel Discussions – Videos

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvements activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.



Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and The Americas Hepato-Pancreato-Biliary Association. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 7.50 *AMA/PRA Category 1 Credits™*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates

Certificates awarding *AMA/PRA Category 1 Credit™* or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a *CME Verification Form*.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Program

Wednesday, January 15, 2014

Program Planning Committee

Thomas A. Aloia, MD, Co-Chair

The University of Texas
MD Anderson Cancer Center
Houston, Texas

John C. Mansour, MD, Co-Chair

The University of Texas
Southwestern Medical Center
Dallas, Texas

Sharon M. Weber, MD, Co-Chair

University of Wisconsin
Madison, Wisconsin

Eren Berber, MD

Cleveland Clinic
Cleveland, Ohio

William C. Chapman, MD

Washington University
School of Medicine
St. Louis, Missouri

Alessandro Landskron Diniz, MD

AC Camargo Cancer Center
Sao Paulo, Brazil

Cristina R. Ferrone, MD

Massachusetts General Hospital
Boston, Massachusetts

William Hawkins, MD

Washington University
School of Medicine
St. Louis, Missouri

William R. Jarnagin, MD

Memorial Sloan-Kettering
Cancer Center
New York, New York

Byrne Lee, MD

City of Hope
Duarte, California

Shishir K. Maithel, MD

Emory University
Atlanta, Georgia

Nipun B. Merchant, MD

Vanderbilt University
Medical Center
Nashville, Tennessee

Carl R. Schmidt, MD

The Ohio State University
Columbus, Ohio

Jean-Nicolas Vauthey, MD

The University of Texas
MD Anderson Cancer Center
Houston, Texas

Theodore H. Welling, III, MD

University of Michigan
Ann Arbor, Michigan

Adam Yopp, MD

University of Texas
Southwestern Medical Center
Dallas, Texas

George Zogopoulos, MD, PhD

McGill University
Montreal, Quebec
Canada

Jill Kawulok

AHPBA
Leawood, Kansas

Nonie Lowry

AHPBA
Leawood, Kansas

Brigitte M. Taylor, CAP

The University of Texas
MD Anderson Cancer Center
Houston, Texas

Constance C. Tierney, CMP

The University of Texas
MD Anderson Cancer Center
Houston, Texas

7:00–7:50 a.m. Continental Breakfast/Registration

7:50–8:00

Introduction

William C. Chapman, MD

8:00–10:30

SESSION I: GALLBLADDER CANCER

Moderators: Felipe José Fernández Coimbra, MD;
William R. Jarnagin, MD

Panelists: Rachna T. Shroff, MD; Elijah Dixon, MD;
Jennifer Knox, MD

8:00–8:20

**Pathologic Evaluation for Patients
With Gallbladder Polyps and Suspicion of
Early Stage Gallbladder Cancer**

Juan Carlos Roa, MD, MSc

8:20–8:30

Discussion

8:30–8:50

**Evaluation and Management
of the Patient Presenting With
a Gallbladder Mass**

Nicolas Járufe Casis, MD

8:50–9:00

Discussion

9:00–9:20

**Incidentally Discovered
Gallbladder Cancer:
The Gallbladder is Out,
Now What Do We Do?**

Shishir K. Maithel, MD

9:20–9:30

Discussion

9:30–9:50

**Advances in Neoadjuvant and
Adjuvant Chemotherapy and Radiation
Approaches to Gallbladder Cancer**

Milind Javle, MD

9:50–10:00

Discussion

10:00–10:30

Break



10:30a.m.–12:30 p.m.

SESSION II: INTRAHEPATIC CHOLANGIOCARCINOMA (IHCCA)

Moderators: Masaru Miyazaki, MD; Sharon M. Weber, MD

Panelists: Ghassan K. Abou-Alfa, MD; Michael A. Choti, MD, MBA;
Michael I. D'Agelica, MD; Jeff Geschwind, MD

10:30–10:50

Recommendations for Diagnosis and Staging of IHCCA

Timothy M. Pawlik, MD, MPH, PhD

10:50–11:00

Discussion

11:00–11:20

Local-Regional Treatment Strategies for IHCCA

Dario Ribero, MD

11:20–11:30

Discussion

11:30–11:50

Hepatobiliary Carcinoma: Defining and Treating An Emerging Entity

Norihiro Kokudo, MD, PhD

11:50–Noon

Discussion

Noon–12:20

Chemotherapy and Radiation Therapy for IHCCA

Eileen M. O'Reilly, MD

12:20–12:30 p.m.

Discussion

12:30–1:30

Lunch at the Movies: Case Presentations With Video

Moderators: David M. Nagorney, MD; Paul D. Greig, MD

Invited Presenters: Thomas A. Aloia, MD; Julie K. Heimbach, MD;
William R. Jarnagin, MD; Nicolas Járufe Casis, MD;
Norihiro Kokudo, MD, PhD; Masaru Miyazaki, MD;
Masato Nagino, MD

1:30–3:30

SESSION III: HILAR CHOLANGIOCARCINOMA

Moderators: John C. Mansour, MD; Jean-Nicolas Vauthey, MD

Panelists: Alessandro Landskron Diniz, MD; Christopher E. Forsmark, MD
Andrew X. Zhu, MD, PhD

1:30–1:50

Multimodality Evaluation of Patients With Suspected Hilar Cholangiocarcinoma: Including When to Proceed Without a Tissue Diagnosis

Thomas A. Aloia, MD

1:50–2:00

Discussion

2:00–2:20

Transplantation for Hilar Cholangiocarcinoma With and Without PSC

Julie K. Heimbach, MD

2:20–2:30

Discussion

2:30–2:50

Resectional Strategies for Hilar Cholangiocarcinoma Including Vascular Resection and the Concept of 'No-Touch'

Masato Nagino, MD

2:50–3:00

Discussion

3:00–3:20

Traditional and Novel Chemotherapy and Radiation Approaches to Hilar Cholangiocarcinoma

Christopher Crane, MD

3:20–3:30

Discussion

3:30–3:40 p.m.

Closing Comments

Sharon M. Weber, MD

Faculty

Ghassan K. Abou-Alfa, MD

Memorial Sloan-Kettering Cancer Center
Weill Medical College at Cornell University
New York, New York

Thomas A. Aloia, MD

The University of Texas
MD Anderson Cancer Center
Houston, Texas

William C. Chapman, MD

Washington University School of Medicine
St. Louis, Missouri

Michael A. Choti, MD, MBA

University of Texas Southwestern
Dallas, Texas

Felipe José Fernández Coimbra, MD

AC Camargo Hospital
Sao Paulo, Brazil

Christopher Crane, MD

The University of Texas
MD Anderson Cancer Center
Houston, Texas

Michael I. D'Angelica, MD

Memorial Sloan-Kettering Cancer Hospital
New York, New York

Alessandro Landskron Diniz, MD

AC Camargo Cancer Center
Sao Paulo, Brazil

Elijah Dixon, MD

University of Calgary
Calgary, Alberta, Canada

Christopher E. Forsmark, MD

University of Florida
College of Medicine
Gainesville, Florida

Jeff Geschwind, MD

Johns Hopkins University
School of Medicine
Baltimore, Maryland

Paul D. Greig, MD

University of Toronto
Toronto, Ontario, Canada

Julie K. Heimbach, MD

Mayo Clinic
Rochester, Minnesota

William R. Jarnagin, MD

Memorial Sloan-Kettering Cancer Center
New York, New York

Nicolas Járufe Casis, MD

Pontificia Universidad Católica de Chile
Santiago, Chile

Milind Javle, MD

The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jennifer Knox, MD, MSc

University of Toronto
Princess Margaret
Toronto, Ontario, Canada

Norihiro Kokudo, MD, PhD

University of Tokyo Graduate School of Medicine
Tokyo, Japan

Shishir K. Maithel, MD

Emory University
Atlanta, Georgia

John C. Mansour, MD

University of Texas Southwestern Medical Center
Dallas, Texas

Masaru Miyazaki, MD

Chiba University Graduate School of Medicine
Chiba, Japan

Masato Nagino, MD, PhD

Nagoya University Graduate School of Medicine
Nagoya, Japan

David M. Nagorney, MD

Mayo Clinic College of Medicine
Rochester, Minnesota

Eileen M. O'Reilly, MD

Memorial Sloan-Kettering Cancer Center
New York, New York

Timothy M. Pawlik, MD, MPH, PhD

Johns Hopkins Hospital
Baltimore, Maryland

Dario Ribero, MD

Ospedale Ordine Mauriziano "Umberto I"
Torino, Italy

Juan Carlos Roa, MD, MSc

Pontificia Universidad Católica de Chile
Santiago, Chile

Rachna T. Shroff, MD

The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jean-Nicolas Vauthey, MD

The University of Texas
MD Anderson Cancer Center
Houston, Texas

Sharon M. Weber, MD

University of Wisconsin
Madison, Wisconsin

Andrew X. Zhu, MD, PhD

Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Registration Information

On-site registration opens at 7:00 a.m. on Wednesday, January 15, 2014 at the San Francisco Marriott Marquis. The opening session of the conference will begin at 7:50 a.m. and the conference will adjourn at 3:40 p.m. on Wednesday, January 15, 2014. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advance registration is January 6, 2014.

There are three ways to register:

- Mail to: CME/Conference Management – Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439
- Fax to: 713-794-1724
- On-line at www.mdanderson.org/conferences

We accept the following forms of payment:

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.


The full conference registration fee includes the tuition, abstract book, breaks, and lunch.

Refund/Cancellation Policy: The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before January 6, 2014. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified either by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact CME/Conference Management at 713-792-2223 or 866-849-5866.



Special Assistance

Contact the Department of CME/Conference Management at 713-792-2223 or 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations

If you are attending the 2014 Gastrointestinal Cancers Symposium, hotel rooms are available at the **San Francisco Marriott Marquis**, 55 Fourth Street, San Francisco, California. Reserve a room through the Symposium website at gicasymp.org.

Ground Transportation

The hotel is approximately 14 miles from San Francisco International Airport and 20 miles from the Oakland Airport. Taxis are available at the approximate price of \$40 one way from SFO and \$60 one way from Oakland. Super Shuttle is also available. Please call 415-558-8500 or book on line at www.supershuttle.com.



The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chair for consideration.

CONFERENCE REGISTRATION - 0638/110845/30070638

AHPBA Sponsored Consensus Conference on the Multidisciplinary Treatment of Bile Duct Cancer - January 15, 2014

Last Name	First	MI	Highest Degree
Department (include box no.)		Specialty	
Institution		Physician ☐ Yes ☐ No	
Street	City	State/Foreign Country/Zip or Mail Code	
Daytime Phone (with area code)	Cell Phone (with area code)	Fax (with area code)	
E-mail Address (please print)			
Emergency Contact	Phone (with area code)	Charge the following: ☐ VISA ☐ MasterCard ☐ American Express	
Credit Card Holder Name (First/Last)		Credit Card Holder Billing Address & ZIP Code	
Credit Card Number		Expiration Date	
MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted			
Business Unit	Department	Fund Group*	Fund Type
Authorized Signature REQUIRED for credit card or IDT		MD Anderson Employee ID No. (REQUIRED)	
IDT Approver Name (First/Last) please print		IDT Approver E-mail	

THIS IS NOT A SELF-MAILER

ADDRESS TO:

AHPBA Sponsored Consensus Conference on the Multidisciplinary Treatment of Bile Duct Cancer

Department of CME/Conference Management – Unit 1381
The University of Texas MD Anderson Cancer Center
PO Box 301439, Houston, TX 77230-1439
or fax to 713-794-1724

Make check or money order payable to:

The University of Texas MD Anderson Cancer Center

FULL CONFERENCE REGISTRATION FEE

- ☐ Postmarked by 1/07/14 \$ 260.00
- ☐ Postmarked after 1/07/14 \$ 300.00
- ☐ Trainees \$125.00
(must provide letter from Director)

Department of CME/Conference Management - Unit 1381
The University of Texas MD Anderson Cancer Center
176700/110845/30070638
PO Box 301439
Houston, TX 77230-1439

Non-Profit Org.
U.S. Postage
PAID
Houston, TX
Permit No. 7052
